Xinuowei Subsidiary Gets Ustekinumab Injection Approval Today

GateNews
According to an announcement today (May 22), Xinuowei's subsidiary Jueshi Biotech received a drug registration certificate from the National Medical Products Administration for ustekinumab injection (brand name: Enyzek), a biosimilar of the original treatment Xidat. The drug is approved for adult patients with moderate to severe plaque psoriasis and patients aged 6 and above.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments